2CUREX — 2cureX AB Share Price
0.000.00%
Last trade - 00:00- SEK14.71m
- SEK9.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.88 | ||
| Price to Tang. Book | 2.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -93.04% | ||
| Return on Equity | -48.06% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | 0.09 | 0.15 | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Directors
- Povl-Andre Bendz CHM (56)
- Fernando Andreu CEO
- Ole Thastrup DCE (65)
- Kenneth Johansen CFO
- Juergen Kupper CEX (53)
- Grith Hagel OTH (59)
- Henrik Harling OTH
- Maarten van der Linden OTH
- Camilla Huse Bondesson DRC
- Joergen Drejer IND (66)
- Timm-H. Jessen IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 4th, 2017
- Public Since
- November 24th, 2017
- No. of Employees
- 14
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 25,102,916
- Address
- c/o Mazars SET Revisionsbyra AB, Box 159, LANDSKRONA, 261 22
- Web
- https://www.2curex.com/
- Phone
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for 2CUREX
2cureX AB Annual Shareholders Meeting
Half Year 2025 2cureX AB Earnings Release
Similar to 2CUREX
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
Alligator Bioscience AB
OMX Nordic Exchange Stockholm
AlzeCure Pharma AB
OMX Nordic Exchange Stockholm
Alzinova AB
OMX Nordic Exchange Stockholm
FAQ
What is the 2cureX AB share price?
As of Today at 19:01 UTC, shares in 2cureX AB are trading at SEK0.59. This share price information is delayed by 15 minutes.
How has the 2cureX AB share price performed this year?
Shares in 2cureX AB last closed at SEK0.59 and the price had moved by +24.68% over the past 365 days. In terms of relative price strength the 2cureX AB share price has outperformed the FTSE Global All Cap Index by +21.56% over the past year.
What are the analyst and broker recommendations for 2cureX AB?
There is no consensus recommendation for this security.
Find out moreWhat is the 2cureX AB dividend yield?
2cureX AB does not currently pay a dividend.
Does 2cureX AB pay a dividend?
2cureX AB does not currently pay a dividend.
When does 2cureX AB next pay dividends?
2cureX AB does not currently pay a dividend.
How do I buy 2cureX AB shares?
To buy shares in 2cureX AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 2cureX AB?
As of the previous close price of SEK0.59, shares in 2cureX AB had a market capitalisation of SEK14.71m.
Where are 2cureX AB shares listed?
Here are the trading details for 2cureX AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: 2CUREX
What kind of share is 2cureX AB?
Based on an overall assessment of its quality, value and momentum 2cureX AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 2cureX AB share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the 2cureX AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 2cureX AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +4.51%.
As of the last closing price of SEK0.59, shares in 2cureX AB were trading +19.6% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 2cureX AB PE Ratio?
The 2cureX AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK0.59.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 2cureX AB?
2cureX AB's management team is headed by:
- Povl-Andre Bendz - CHM
- Fernando Andreu - CEO
- Ole Thastrup - DCE
- Kenneth Johansen - CFO
- Juergen Kupper - CEX
- Grith Hagel - OTH
- Henrik Harling - OTH
- Maarten van der Linden - OTH
- Camilla Huse Bondesson - DRC
- Joergen Drejer - IND
- Timm-H. Jessen - IND